Dozens of trials testing GLP-1 drugs like semaglutide, the medicine in Ozempic and Wegovy, against a placebo suggest that ...

The study supports prior research that found the same thing.

A new review of clinical trial data finds evidence that GLP-1 drugs can meaningfully reduce dementia risk in people with type ...

GLP-1 and SGLT2 drugs — could significantly reduce the risk of developing dementia in life, a large new study has found.

Obesity and diabetes drugs, particularly semaglutides like Wegovy and Ozempic, may reduce a person’s risk of dementia, a new ...

Two studies suggested the diabetes/weight-loss drug may have a beneficial side effect—but more work is needed to confirm this.

Weight loss drugs like Ozempic gained popularity for managing obesity, diabetes, and related chronic conditions, a new study ...

Diabetes and weight loss treatments such as Ozempic and Wegovy, known as GLP-1 agonists, could significantly reduce the risk of developing any type of dementia, according to a meta-analysis of 26 ...

Two new studies published in JAMA Neurology reveal that GLP-1 receptor agonists, like Ozempic and Trulicity, may ...

It’s possible that they may play a role as a preventative measure in the future,” said Dr. Catriona Reddin told The Post.

Medications designed to treat diabetes by lowering blood sugar levels, like Ozempic, continue to turn up added benefits, and ...

Semaglutide is available as Wegovy and Ozempic injections, and also as Rybelsus tablets. The study's findings indicate a potential link between these medications and a lower risk of dementia.